Caliway Biopharmaceuticals Co (TPE:6919) Net Income (Continuing Operations) : NT$-545.92 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Caliway Biopharmaceuticals Co's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was NT$-175.57 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-545.92 Mil.

Caliway Biopharmaceuticals Co Net Income (Continuing Operations) Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co Net Income (Continuing Operations) Chart

Caliway Biopharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-98.49

-224.29

-286.16

-488.46

-588.83

Caliway Biopharmaceuticals Co Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial									-218.47	-176.65	-137.57	-56.14	-175.57

Caliway Biopharmaceuticals Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-545.92 Mil.

Caliway Biopharmaceuticals Co (TPE:6919) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Caliway Biopharmaceuticals Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Caliway Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (TPE:6919) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.99, Sec. 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221

Website

https://www.caliway.com.tw

Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. Its pipeline candidates are CBL-514, CBA-539, and CBO-012.

Caliway Biopharmaceuticals Co Headlines

No Headlines